Collaboration is in our name, and we mean it. We want more health economists working in this field, not fewer. We share our methods openly and design studies that others can build on.

Equity is not a separate line of work for us. It decides which questions are worth asking. The people most likely to benefit from psychedelic therapies are often the least able to pay for them, and coverage is where that gets settled. We study who reaches these therapies and who is left out — by insurance status, by income, by geography, and by country — and those questions are built into study design from the start rather than added at the end.

Access for all. The populations Medicaid serves have the highest need for these therapies, yet the least access. Insurers hesitate without evidence they can trust, so we provide that evidence, replacing uncertainty with the confidence to move forward on coverage.

Our outlook is global. The questions of access and equity do not stop at national borders. As the field grows, we are turning increasingly toward low- and middle-income countries, where the need is greatest and the evidence is thinnest.